Sabitlenmiş Tweet

The @US_FDA's own scientists said no to peptides. The panel that actually votes was just built to overrule them.
I prescribe these, so here's the part the headlines are skipping.
Ahead of the July 23-24 advisory meeting, FDA career staff put it in writing: Keep all 7 peptides under review (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, DSIP) off the 503A list.
Licensed pharmacies can't legally compound those peptides unless they are on that list.
If it were just up FDA staff, those peptides' fates would be sealed. But staff don't get the final say. An advisory committee votes first. And @HHSGov just rebuilt that committee with 8 new members, most of whom run or profit from peptide businesses. Put plainly, it was stacked to vote yes.
So this isn't "peptides are dead." It's career FDA staff against a hand-picked pro-peptide panel, and the agency writes the actual rule afterward.
What I actually care about is what happens to patients.
The gray-market peptide world deserves scrutiny. Purity is a genuine problem. But cutting off regulated compounding doesn't make peptides safer. It just sends people somewhere worse.
Watch July 23 and 24. Two FDAs collide, and your access hangs on it.
h/t @RxRegA, who surfaced the FDA briefing doc.

English


















